文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

碳青霉烯与非碳青霉烯β-内酰胺类作为产超广谱β-内酰胺酶肠杆菌目尿源性脓毒性休克经验性治疗的疗效:倾向加权多中心队列研究

Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study.
PubMed 文献 · Ann Intensive Care · 2023-03-24
一句话结论在产ESBL肠杆菌目尿源性脓毒性休克中,含氨基糖苷类的非碳青霉烯经验性方案与碳青霉烯方案相比30天死亡率无显著差异(15% vs 7%,OR=1.99,p=0.16)。

这项回顾性倾向加权多中心观察性研究在11个ICU开展,评估非碳青霉烯方案(哌拉西林-他唑巴坦+氨基糖苷类或第三代头孢菌素+氨基糖苷类)作为产超广谱β-内酰胺酶肠杆菌目(ESBL-E)尿源性脓毒性休克经验性治疗,与碳青霉烯方案相比的疗效,主要终点为30天死亡率。共纳入156例患者,69例接受碳青霉烯、87例接受非碳青霉烯经验性治疗,两组基线临床特征相似。碳青霉烯组30天死亡率为15%(10/69),非碳青霉烯组为7%(6/87),OR=1.99(95%CI 0.55–5.34),p=0.16,无显著差异;疾病严重程度、脓毒性休克缓解率、ESBL-E感染复发率及艰难梭菌继发感染率两组相当。作者结论认为,在ESBL-E尿源性脓毒性休克中,含氨基糖苷类的非碳青霉烯经验性方案与碳青霉烯方案相比未伴随更高死亡率。

要点

  • ESBL-E尿源性脓毒性休克经验性使用含氨基糖苷类的非碳青霉烯方案,30天死亡率15%(10/69)vs 7%(6/87),OR=1.99(95%CI 0.55–5.34),p=0.16,无显著差异。
  • 该回顾性倾向加权多中心队列纳入11个ICU共156例,69例碳青霉烯、87例非碳青霉烯,两组基线临床特征相似。
  • 疾病严重程度、脓毒性休克缓解率、ESBL-E感染复发率及艰难梭菌继发感染率在两组间相当。
  • 作者结论:在ESBL-E尿源性脓毒性休克中,含氨基糖苷类的非碳青霉烯经验性方案与碳青霉烯方案相比未伴随更高死亡率。

适用人群与场景

  • 11个ICU中发生产超广谱β-内酰胺酶肠杆菌目(ESBL-E)尿源性脓毒性休克、接受经验性抗菌治疗的患者,共156例(碳青霉烯组69例,非碳青霉烯组87例)。

研究设计与关键结果

  • 研究类型:回顾性倾向加权多中心观察性研究,在11个ICU开展,纳入156例ESBL-E尿源性脓毒性休克患者,比较非碳青霉烯方案(哌拉西林-他唑巴坦+氨基糖苷类或第三代头孢菌素+氨基糖苷类)与碳青霉烯经验性治疗,主要终点为30天死亡率。
  • 30天死亡率:碳青霉烯组15%(10/69)vs 非碳青霉烯组7%(6/87),OR=1.99(95%CI 0.55–5.34),p=0.16。
  • 两组基线临床特征相似;疾病严重程度、脓毒性休克缓解率、ESBL-E感染复发率及艰难梭菌继发感染率在两组间相当。

证据类型、等级与局限

  • 证据类型:回顾性倾向加权多中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在ESBL-E尿源性脓毒性休克中,含氨基糖苷类的非碳青霉烯经验性方案与碳青霉烯方案相比未伴随更高死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The rise in antimicrobial resistance is a global threat responsible for about 33,000 deaths in 2015 with a particular concern for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) and has led to a major increase in the use of carbapenems, last-resort antibiotics.

METHODS: In this retrospective propensity-weighted multicenter observational study conducted in 11 ICUs, the purpose was to assess the efficacy of non carbapenem regimen (piperacillin-tazobactam (PTZ) + aminoglycosides or 3rd-generation cephalosporin (3GC) + aminoglycosides) as empiric therapy in comparison with carbapenem in extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) urinary septic shock. The primary outcome was Day-30 mortality.

RESULTS: Among 156 patients included in this study, 69 received a carbapenem and 87 received non carbapenem antibiotics as empiric treatment. Baseline clinical characteristics were similar between the two groups. Patients who received carbapenem had similar Day-30 mortality (10/69 (15%) vs 6/87 (7%), OR = 1.99 [0.55; 5.34] p = 0.16), illness severity, resolution of septic shock, and ESBL-E infection recurrence rates than patients who received an empiric non carbapenem therapy. The rates of secondary infection with C. difficile were comparable.

CONCLUSIONS: In ESBL-E urinary septic shock, empiric treatment with a non carbapenem regimen, including systematically aminoglycosides, was not associated with higher mortality, compared to a carbapenem regimen.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Cariou E, Griffier R, Orieux A, et al. Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study. Ann Intensive Care. 2023. PMID: 36959425. doi:10.1186/s13613-023-01106-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。